MRNS Marinus Pharmaceuticals Inc.

4.28
+0.65  (+18%)
Previous Close 3.63
Open 3.64
Price To Book 4.92
Market Cap 173447056
Shares 40,525,013
Volume 1,630,911
Short Ratio
Av. Daily Volume 1,342,693

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Data due 1H 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 trial initiation announced June 19, 2018.
Ganaxolone
CDKL5 disorder
Phase 2 data due 1H 2019
Ganaxolone - oral (Amaryllis)
Postpartum depression

Latest News

  1. Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
  2. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  3. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  4. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
  5. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  6. Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
  7. Marinus Pharmaceuticals plans $45M stock sale
  8. Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  9. Here's Why Marinus Pharmaceuticals Is Sinking Today
  10. The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
  11. Marinus Pharmaceuticals Announces Public Offering of Common Stock
  12. Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials
  13. Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
  14. Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
  15. Granite Point Capital’s Returns, AUM, and Holdings
  16. Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
  17. Marinus Pharmaceuticals: 3Q Earnings Snapshot